Department of Parasitology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
Cell Rep. 2022 Jul 5;40(1):111032. doi: 10.1016/j.celrep.2022.111032.
How mechanistic target of rapamycin complex 1 (mTORC1), a key regulator of cellular metabolism, affects dendritic cell (DC) metabolism and T cell-priming capacity has primarily been investigated in vitro, but how mTORC1 regulates this in vivo remains poorly defined. Here, using mice deficient for mTORC1 component raptor in DCs, we find that loss of mTORC1 negatively affects glycolytic and fatty acid metabolism and maturation of conventional DCs, particularly cDC1s. Nonetheless, antigen-specific CD8 T cell responses to infection are not compromised and are even enhanced following skin immunization. This is associated with increased activation of Langerhans cells and a subpopulation of EpCAM-expressing cDC1s, of which the latter show an increased physical interaction with CD8 T cells in situ. Together, this work reveals that mTORC1 limits CD8 T cell priming in vivo by differentially orchestrating the metabolism and immunogenicity of distinct antigen-presenting cell subsets, which may have implications for clinical use of mTOR inhibitors.
雷帕霉素靶蛋白复合物 1(mTORC1)作为细胞代谢的关键调节剂,其如何影响树突状细胞(DC)代谢和 T 细胞启动能力主要在体外进行了研究,但 mTORC1 在体内如何调节这一过程仍知之甚少。在这里,我们使用 DC 中缺乏 mTORC1 成分 raptor 的小鼠发现,mTORC1 的缺失会负调控糖酵解和脂肪酸代谢以及常规 DC,特别是 cDC1 的成熟。尽管如此,针对感染的抗原特异性 CD8 T 细胞反应并未受损,甚至在皮肤免疫接种后增强。这与朗格汉斯细胞和表达 EpCAM 的 cDC1 亚群的激活增加有关,其中后者在原位显示与 CD8 T 细胞的物理相互作用增加。总之,这项工作揭示了 mTORC1 通过差异调节不同抗原呈递细胞亚群的代谢和免疫原性来限制体内 CD8 T 细胞的启动,这可能对 mTOR 抑制剂的临床应用具有重要意义。